活动性糖尿病黄斑水肿患者白内障手术围术期抗VEGF治疗结局
PURPOSE: To investigate the outcomes of cataract surgery in patients with active diabetic macular edema (DME) who are receiving active treatment with intravitreal anti-vascular endothelial growth factor (VEGF) injections in the perioperative period.…
要点
- 活动性DME患者接受白内障手术并围术期抗VEGF治疗,术后视力显著改善。
- 45.9%术眼出现新发或加重的术后DME,但未立即影响最佳矫正视力。
- 出现新发积液的术眼术后1个月和6个月黄斑中心凹厚度显著增加。
核心结论
- 在真实世界环境中,合并活动性DME且正在接受抗VEGF治疗的白内障患者可接受白内障手术,但可能出现DME加重而未立即影响最佳矫正视力。
研究设计与样本
- 回顾性临床队列研究,纳入2012年1月1日至2017年12月31日期间接受白内障手术并接受玻璃体腔抗VEGF注射的患者。
主要发现
- 所有术眼手术前后最佳矫正视力比较有显著改善(P < .0001)。
- 手术前后黄斑中心凹厚度无显著差异(P > .05)。
- 术前OCT扫描显示30只眼(81.1%)存在积液。
- 17只眼(45.9%)出现新发或加重的术后DME,但术后视力在发生与未发生DME加重的术眼间无差异(P > .05)。
- 出现新发积液的术眼术后1个月黄斑中心凹厚度为350 μm vs 320 μm(P = .036),术后6个月为342 μm vs 305 μm(P = .013),均显著增加。
临床怎么用
- 对于合并活动性DME且正在接受抗VEGF治疗的白内障患者,可在围术期继续抗VEGF治疗的前提下考虑白内障手术。
- 术后应监测DME新发或加重,即使最佳矫正视力未见明显下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the outcomes of cataract surgery in patients with active diabetic macular edema (DME) who are receiving active treatment with intravitreal anti-vascular endothelial growth factor (VEGF) injections in the perioperative period. DESIGN: Retrospective clinical cohort study. METHODS: We reviewed all patients who underwent cataract surgery and were receiving intravitreal anti-VEGF injections from January 1, 2012 through December 31, 2017. Thirty-seven eyes underwent cataract surgery and received ≥1 intravitreal anti-VEGF injection for a diagnosis of DME within 6 months before surgery. Outcome measures included the development of subretinal or intraretinal fluid in the 6 months after surgery, timing of injections, number of injections, best-corrected visual acuity, and central subfield thickness. RESULTS: There was a significant improvement between pre- and postoperative best-corrected visual acuity when comparing all eyes (Ps < .0001) and no significant difference in central subfield thickness before and after surgery (P > .05). There were 30 eyes (81.1%) that had fluid on the preoperative optical coherence tomography scan. Seventeen eyes (45.9%) developed new or worsening postoperative DME. Comparing the eyes that did or did not develop worsening DME, there were no differences in postoperative visual acuities (P > .05). Eyes that did develop new fluid had significant increases in postoperative central subfield thickness at both 1 month (350 vs 320 μm, P = .036) and 6 months (342 vs 305 μm, P = .013). CONCLUSION: In a real-world setting, patients with cataracts and actively treated DME may undergo cataract surgery but may see a worsening of DME not immediately affecting the best-corrected visual acuity.
引用
- Starr MR, Mahr MA, Smith WM, et al. Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2021. PMID: 33852907. doi:10.1016/j.ajo.2021.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。